Review

Current and Potential Pharmacologic Therapies for Traumatic Brain Injury

Jowy Tani 1,2,3,4,5,6,7, Ya-Ting Wen 7,8,9, Chaur-Jong Hu 4,7,10 and Jia-Ying Sung 1,4,7,*

1 Department of Neurology, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan; jowytani@tmu.edu.tw
2 Sleep Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan
3 Biomed Innovation Center, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan
4 Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; chaurjongh@tmu.edu.tw
5 Taipei Medical University Biomed Accelerator, Taipei Medical University, Taipei 106, Taiwan
6 Taipei Medical University Biodesign Center, Taipei Medical University, Taipei 106, Taiwan
7 Taipei Neuroscience Institute, Taipei Medical University, Taipei 110, Taiwan; 98142@w.tmu.edu.tw
8 Department of Neurosurgery, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan
9 Department of Neurosurgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
10 Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan
* Correspondence: sung.jiaying@tmu.edu.tw; Tel.: +886-2-2930-7930 (ext. 6940)

Abstract: The present article reviewed the pharmacologic therapies of traumatic brain injury (TBI), including current and potential treatments. Pharmacologic therapies are an essential part of TBI care, and several agents have well-established effects in TBI care. In the acute phase, tranexamic acid, antiepileptics, hyperosmolar agents, and anesthetics are the mainstay of pharmacotherapy, which have proven efficacies. In the post-acute phase, SSRIs, SNRIs, antipsychotics, zolpidem and amantadine, as well as other drugs, have been used to manage neuropsychological problems, while muscle relaxants and botulinum toxin have been used to manage spasticity. In addition, increasing numbers of pre-clinical and clinical studies of pharmacologic therapies for TBI have been published recently, which could contribute to the addition of new agents into standard TBI management in the future. This review discusses current and potential pharmacologic therapies for TBI. We also summarize the pharmacologic therapies for TBI in Figure 1.

Keywords: traumatic brain injury; pharmacologic therapies; psychopharmacology; neuroprotectants

1. Introduction

Traumatic brain injury (TBI) is a sudden injury that causes damage to the brain. Sixty-nine million individuals worldwide are estimated to sustain a TBI each year [1]. Pharmacologic therapies play important roles in mild to severe TBI. There are several pharmacologic therapies recommended by guidelines, which have proven efficacies and well-documented safety profiles for use in acute and post-acute TBI patients [2]. In addition, several new preclinical and clinical studies of pharmacologic therapies for TBI have been published recently, which could contribute to the addition of new agents into standard TBI management in the future. This review discusses current and potential pharmacologic therapies for TBI. We also summarize the pharmacologic therapies for TBI in Figure 1.
Figure 1. Established and potential pharmacologic therapies for traumatic brain injury. Potential pharmaceutical agents may be accepted into standard practice (“go above the surface”) with the accumulation of clinical evidence.

2. Established Pharmacologic Therapies for TBI

Following traumatic brain injury, primary damage results from mechanical damage affecting cells and tissue. Hemorrhage and breakdown of the blood–brain barrier (BBB) also happen within seconds to minutes. Secondary damage develops within minutes, with the development of inflammation, ischemia and edema [3].

Subsequent processes, including delayed inflammation, vasospasm, cell death and genomic responses, develop within days. Cellular degeneration, neuropsychiatric co-
morbidities and muscle spasticity are noted over the next few weeks to months. Recent advances in biomarkers, including microRNA, have enhanced our understanding of the pathophysiologic process and could even help researchers to determine the time elapsed since an injury [3–5]. In current practice, pharmacological therapies are provided to treat both the acute and chronic effects of these pathological processes.

Published literature studying the effects of biological sex and gender shows mixed outcomes on TBI. A recent review of the literature found that women, after puberty but before menopause, were at higher risk of poor outcome, while postmenopausal women fared better than men of similar age [6]. Care pathways and treatment probably did not differ significantly between women and men [7]. More study is needed to support treatment strategies for different sexes.

2.1. Acute Treatments for TBI

2.1.1. Tranexamic Acid

Tranexamic acid reduces the risk of death in mild to moderate TBI patients when treatment is given within 3 h, in a loading dose of 1 g, followed by infusion of 1 g for 8 h, according to a recent CRASH-3 trial [8]. However, tranexamic acid does not reduce death in severe TBI patients who have extensive intracranial hemorrhage.

2.1.2. Treatments for Coagulopathies

Around one-third of severe TBI patients demonstrate coagulopathy, which may lead to hemorrhage enlargement and poor neurologic outcomes. Coagulopathy mostly results from existing medications, such as aspirin, clopidogrel, direct oral anticoagulants or warfarin. It has been demonstrated that direct oral anticoagulants do not increase the incidence of intracranial hemorrhage [9], and there are better outcomes for direct oral anticoagulant use compared to warfarin use, even with low use of the reversal strategy [10,11].

Patients taking warfarin could be managed with vitamin K and fresh frozen plasma (FFP) infusion, monitoring prothrombin time/international normalized ratio (INR) 30 min after transfusion or every 4 to 6 h to ensure INR < 1.4 [12].

In patients using anti-platelet agents or thrombocytopenia, a platelet count > 95,000/µL directly with platelet transfusion should be maintained. In one cohort study, a platelet count < 135,000/µL was associated with a 12.4 times higher risk of hemorrhage enlargement; patients with a platelet count < 95,000/µL were 31.5 times more likely to require neurosurgical intervention [13].

2.1.3. Hyperosmolar Agents

Mannitol and hypertonic saline are commonly used in the management of intracranial hypertension and cerebral edema. Mannitol at bolus doses of 0.25–1 g/kg every 4 to 6 h is effective in reducing brain volume, and thus lowering intracranial pressure (ICP) [2]. However, its diuretic effect should be monitored cautiously in hypotensive patients. Mannitol is not recommended in patients with systolic blood pressure < 90 mm Hg.

Hypertonic saline is also an effective hyperosmolar agent for lowering increased ICP [14,15]. Infusion of 3% hypertonic saline is administrated to achieve a sodium level goal of 145–155 mEq/L. There is less volume depletion and hypovolemia, which makes hypertonic saline safer in major trauma patients with ongoing volume loss and hypotension. When comparing these two hyperosmolar agents, there was no strong evidence to suggest the superiority of either in improving mortality or functional recovery [16,17].

2.1.4. Anesthetics and Sedatives

Anesthetics and sedatives are commonly used in acute stage TBI management in the intensive care unit (ICU) setting. Barbiturates and propofol have both been shown to depress cerebral metabolism, decrease oxygen consumption, lower ICP and prevent seizures. They are recommended as adjuvant therapy to control elevated ICP when refractory to maximum hyperosmolar therapy and surgical decompression. However, hemodynamic
stability should be monitored during barbiturate or propofol therapy. Barbiturates result in a decrease in blood pressure in 25% of patients [18]. Body temperature is also significantly lower. Therefore, the duration and dose of barbiturate administration need to be carefully observed. It could be used under continuous monitoring of EEG to achieve optimal doses.

Within the ICU, propofol is even more widely used in acute TBI management. It is easier to control the treatment effects because of its rapid onset and short duration characteristics. However, caution is required, as high-dose propofol can result in morbidity. Propofol infusion syndrome could lead to hyperkalemia, metabolic acidosis, hyperlipidemia, myocardial failure and renal failure, which may result in death. Therefore, extreme caution must be taken when using propofol doses > 4 mg/kg/h, or when use exceeds 48 h. For refractory ICP elevation, pentobarbital and thiopental infusions may be used [18]. Nevertheless, the therapy may delay timely neurologic examination. It may also result in hypotension, ileus, ventilator-associated pneumonia and metabolic acidosis.

2.1.5. Drugs for Prevention of Thromboembolism

Heparin or low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in TBI patients is generally safe if initiated within 24–48 h of injury [19].

2.1.6. Antiepileptics

The general incidence of post-traumatic seizure in hospitalized populations of TBI is about 3–5% [20,21]. In a study enrolling 5984 TBI patients in Minnesota from 1935 to 1984, the incidence of seizures ranged between 0.7 and 10% in five years of follow-up, correlating with the severity of TBI [22]. The use of antiepileptic drugs in the acute management of TBI has been proven to reduce the incidence of early seizures, but does not prevent the later development of epilepsy.

Furthermore, subclinical seizures detected from an electroencephalogram may be as high as 20–25% [23]. Thus, it is recommended to use prophylactic antiepileptic drugs to avoid early seizures after TBI (within 7 days of injury) [24]. Antiepileptics are recommended in the first seven days following injury in guidelines. Continued use of antiepileptics is recommended if there are electroencephalogram (EEG) discharges. Use of antiepileptics prevents post-traumatic seizures, but does not prevent later development of epilepsy [25,26].

Carbamazepine and valproate are also used as mood stabilizers for psychomotor agitation after TBI, but the effects are controversial [27]. A newer antiepileptic drug, levetiracetam, is commonly used as there is less drug interaction and it has an equal effect as phenytoin in preventing early seizures [28]. The optimal duration of prophylactic antiepileptic drugs is uncertain and depends on the severity of brain injury. In the absence of early seizures, antiepileptic drugs are usually continued throughout the hospital stay and are discontinued within the first few weeks of discharge [29,30].

A recent meta-analysis study at World Neurosurgery, comparing the efficacy of phenytoin, levetiracetam and valproate in preventing early seizures in TBI patients, showed that phenytoin was the most studied drug. Phenytoin has level 2a evidence to decrease the incidence of early post-traumatic seizures [31]. However, more studies are needed to assess the efficacy of other antiepileptic drugs, such as levetiracetam and valproate. Currently, there is insufficient evidence to recommend levetiracetam or valproate over phenytoin.

2.1.7. Antipyretics

Fever could lead to worse outcomes after TBI, and antipyretics could be used to control fever in acute TBI. Maintenance of normothermia also improves ICP control [32] and brain tissue oxygenation [33].

2.2. Treatments for Post-TBI Neuropsychiatric Changes

Neuropsychiatric changes following TBI could cause significant distress in patients and long-term disability [34]. The choice of pharmacologic treatments could have a significant impact on post-acute TBI care, as well as the patient’s neurological recovery [35]. The
present review further discusses pharmaceutical agents that have been studied for their use in post-acute TBI.

2.2.1. SSRIs and SNRIs

Several studies have been conducted on the efficacies of various selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression. Sertraline [36], citalopram [36,37], and fluoxetine [36] have been shown to be beneficial in the treatment of post-TBI depression. Sertraline could even potentially prevent the later onset of depression [38,39]. Sertraline probably does not improve arousal in TBI patients [40].

SSRIs [41], including citalopram [42], sertraline [43] and paroxetine [44], could improve post-TBI pathological laughing and crying. Fluvoxamine and fluoxetine could probably improve apathy [45].

Serotonin and norepinephrine re-uptake inhibitors (SNRIs), such as milnacipran, have also been shown to be efficacious in the treatment of depression [46]. Another SNRI, atomoxetine, has failed to improve attention, speed of memory or working memory, compared to a placebo [47].

2.2.2. Trazodone

Trazodone may cause impaired attention and errors with memory tests [48], but has mixed results on sleep [49].

2.2.3. TCAs

Desipramine has been shown to improve depression in severe TBI [50]. However, tricyclic antidepressants (TCAs) are probably less effective than SSRIs in the treatment of post-TBI depression [51,52], and are associated with more complications [53].

2.2.4. Buspirone

Buspirone is a serotonin 1A receptor partial agonist that has been shown to reduce anxiety in patients with TBI [54].

2.2.5. Antipsychotics

Typical antipsychotics, including methotrimeprazine [55], droperidol, haloperidol [56] and loxapine [57], could improve agitation. Atypical antipsychotics, including quetiapine [58], clozapine [59], ziprasidone [60] and aripiprazole [61], have also been shown to improve agitation. Olanzapine has been shown to improve post-TBI psychosis [62,63]. Atypical antipsychotics are generally preferred over typical antipsychotics in post-TBI patients, due to their more favorable profile in safety and neurorecovery [64].

2.2.6. Levodopa/Carbidopa

Levodopa/carbidopa has been shown to improve consciousness [65].

2.2.7. Bromocriptine

Bromocriptine is a direct dopamine agonist at the D2 receptor. It could improve arousal [66], but probably could not improve attention [67].

2.2.8. Prazosin

Prazosin has been shown to reduce daytime sleepiness, improve headaches and improve cognition [68].

2.2.9. Beta Blockers

Beta blockers, such as propranolol and pindolol, have been shown to reduce post-TBI agitation in some studies [69]. Nevertheless, their hypotensive effect may limit the dose that could be applied.
2.2.10. Amantadine

Amantadine has been shown to improve the pace of functional recovery, as measured by the Disability Rating Scale (DRS) [70]. It has also been shown to improve early arousal in the acute phase of TBI [71–73].

2.2.11. Lamotrigine

Lamotrigine has been shown to reduce aggressive behavior in TBI patients [74].

2.2.12. Modafinil and Methylphenidate

Modafinil could probably improve excessive daytime sleepiness [75], but probably does not improve fatigue [76]. It might be able to improve sleep latency in patients with mild or moderate TBI [77]. Methylphenidate has been shown to improve post-TBI attention and processing speed [78–81].

2.2.13. Lisdexamfetamine Dimesylate

Lisdexamfetamine dimesylate has been shown to improve attention and working memory in a small-scale study [82].

2.2.14. Rivastigmine and Donepezil

Rivastigmine and donepezil are well known for their use in the treatment of Alzheimer’s disease. Donepezil is currently undergoing clinical studies to confirm its effect on memory, attention and processing speed [83]. Rivastigmine did not appear to improve cognition significantly [84], but it showed some improvement in memory in some subgroups of patients in a post hoc analysis of one study [85].

2.2.15. Benzodiazepines and Zolpidem

Benzodiazepines are associated with attentional and memory impairments in TBI, and are generally to be avoided [86,87]. They may impair coordination, leading to falls, increase sedation, negatively affect memory [49], and they may also lead to sleep–wake disturbances [88].

Interestingly, zolpidem has been shown to cause a temporary response in a fraction of patients with severe TBI [89]. It could probably cause attenuation of inter-hemispheric coherences on electroencephalograms [90], and improved cerebral perfusion was observed on single-photon emission computed tomography (SPECT) [91].

2.2.16. Melatonin and Ramelteon

Melatonin might be able to improve daytime sleepiness in TBI patients [92]. Ramelteon has been shown to improve total sleep time and could potentially improve cognition [93].

2.3. Other Pharmaceutical Agents for Post-Acute TBI Care

2.3.1. Muscle Relaxants

Spasticity is an important problem, particularly in moderate and severe TBI. Oral baclofen could improve the lower extremity Modified Ashworth Score [94]. Intrathecal baclofen might be able to improve muscle spasms even more than oral baclofen [95]. Oral tizanidine has been shown to reduce the Ashworth score, enhance motor strength and reduce muscle tone [96].

2.3.2. Botulinum Toxin

A botulinum toxin injection might also be beneficial in the treatment of spasticity in TBI patients [97]. Botulinum toxin might also improve chronic post-traumatic headache [98].

2.3.3. Agents for Paroxysmal Sympathetic Hyperactivity Management

The various drugs discussed above are used for the prevention and/or abortion of paroxysmal sympathetic hyperactivity (PSH), which occurs in up to 10% of patients with
severe TBI. Drugs that have been studied for the treatment of PSH in TBI include beta blockers, benzodiazepines, bromocriptine [99], dantrolene [100] and gabapentin [101].

3. Potential Therapies for TBI

3.1. Neuroprotective Approaches Previously Evaluated in Clinical Studies

Several pharmaceutical agents have been evaluated in clinical studies for their potential efficacies in the treatment of TBI. So far, the routine use of most of these agents in the management of TBI has not been justified. Nevertheless, future evidence may arise to support their use in the care of TBI patients.

3.1.1. Corticosteroids

Corticosteroid was one of the first agents studied for its neuroprotective effect in TBI. The use of corticosteroids has been studied in the Medical Research Council’s Corticosteroid Randomization after Significant Head Injury study [102,103]. This large-scale study found that treatment with glucocorticoids increased mortality.

3.1.2. Citicoline

Citicoline is a cholinergic agent that increases the formation of ATP. It was evaluated in a multi-center, double-blind, randomized phase III controlled trial, The Citicoline Brain Injury Treatment Trial (COBRIT), but it did not improve outcomes [104].

3.1.3. Progesterone

Despite the potential benefits shown in two older, small-scale studies [105,106], progesterone has been evaluated by two large-scale clinical trials: SYNAPSe and ProTECT III [107,108], but did not demonstrate clinical benefit in patient mortality and functional outcomes. Some clinical studies suggested that progesterone might be neuroprotective [109,110].

3.1.4. Erythropoietin

One randomized controlled trial showed that erythropoietin treatment results in lower mortality, but that result is not statistically significant [111]. Two meta-analyses of trials also suggested that erythropoietin might lower mortality, but not reduce poor functional outcomes [112,113]. Other studies have not revealed evidence of improved outcomes from erythropoietin use [114].

3.1.5. Magnesium

The use of magnesium has been evaluated in a number of heterogeneous clinical studies [115,116]. A meta-analysis concluded that while all-cause mortality did not improve in the treatment group, the GCS might have improved [115].

3.1.6. Cyclosporine

Cyclosporine has been evaluated in a few small-scale clinical trials, and did not appear to contribute to a favorable outcome [117,118].

3.1.7. Glibenclamide

Glibenclamide is an antagonist of sulfonylurea receptor 1 (SUR1). It has been evaluated in several small-scale clinical studies and showed favorable outcomes, such as an improved Glasgow Coma Scale (GCS) score and improved Glasgow Outcome Scale (GOS) score [119–122].

3.1.8. Statins

Clinical studies of statins in TBI patients suggested that statin use might improve functional outcomes. It might also lead to a reduction in pro-inflammatory mediators [123–125].
3.2. Neuroprotective Approaches and Natural Therapies Previously Evaluated in Pre-Clinical Studies

3.2.1. PPAR Agonists

Peroxisome proliferator-activated receptor (PPAR) agonists, such as rosiglitazone pioglitazone, play a role in the regulation of gene transcriptions, which are essential in metabolic processes and cell differentiation. Its neuroprotective properties were suggested in several pre-clinical studies [126]. It might exert such an effect by decreasing axonal injury, decreasing apoptosis, decreasing autophagy and/or decreasing microglial activation [126–128].

3.2.2. Vitamins

Vitamin D could reduce inflammation biomarkers and prevent neuron death in animal models when it is used together with progesterone [129]. Vitamin E has been reported to enhance the neuroprotective effects of progesterone [130]. Water-soluble nicotinamides aggregate the functional recovery of TBI rodents [131,132]. An equivocal effect of folic acid has been documented [133,134]. However, there is an overall lack of clinical trials on vitamins for TBI patients.

3.2.3. Zinc

Zinc has been shown to have double effects on both anti-inflammation and antioxidative damage [135]. High zinc supplements might decrease neuropsychiatric symptoms in TBI patients, based on animal experiment results [136–138].

3.2.4. DHA

Docosahexaenoic (DHA) is a fatty acid that exists in phospholipids of the neuron membrane. It can be released to counteract glutamate overactivity after brain damage [139]. DHA can also reduce endoplasmic reticulum (ER) stress and prevent abnormal protein accumulation in the TBI model [140]. DHA is quite a safe and accessible food supplement and might be beneficial for neuroprotection in traumatic brain injury; however, human clinical studies are necessary.

3.2.5. Dietary Supplements

Curcumin has been reported to improve the motor and learning ability in TBI animal models [141]. Resveratrol has been shown to reduce reactive oxygen species (ROS), inhibit excitotoxicity and decrease inflammation in cortical injury models of TBI [142]. Lipoic acid could stabilize plasma membranes and prevent NADPH (nicotinamide adenine dinucleotide phosphate) oxidative stress in mild TBI rats. In a clinical trial [143], Enzogenol has been shown to take advantage of the cognitive function in TBI patients. Both nutrients and pharmacological treatment are important for the recovery of TBI. A low nutrient intake in TBI is correlated with poor outcomes [144].

4. Conclusions

Figure 2 shows the use of each type of pharmacologic agent, in various phases of alteration within central nervous system (CNS) physiology, following traumatic brain injury. Table 1 shows current pharmaceutical therapies for TBI, based on the timing of use, and main effects on the CNS.
4. Conclusions

Figure 2 shows the use of each type of pharmacologic agent, in various phases of alteration within central nervous system (CNS) physiology, following traumatic brain injury. Table 1 shows current pharmaceutical therapies for TBI, based on the timing of use, and main effects on the CNS.

![Pharmacological therapies in current practice](image)

**Table 1. Current pharmaceutical therapies for TBI.**

| Pharmaceutical Agents | Effects on CNS | Timing of Usage | Role in TBI Treatment | Reference |
|------------------------|----------------|-----------------|-----------------------|-----------|
| **Acute phase**        |                |                 |                       |           |
| Tranexamic acid        | Antifibrinolytics | Within 3 h of injury | Reduces the risk of death in mild to moderate TBI | [8]       |
| Vitamin K, FFP, Direct oral anticoagulants reversal agents | Coagulopathy reversal agents | Immediately after coagulopathy is identified | Reversal of coagulopathies | [9–13]|
| Mannitol and hypertonic saline | Elevates blood plasma osmolality, drawing water from brain and CSF | When impending cerebral herniation is noted; assessment in every 1–2 h | Management of intracranial hypertension and cerebral edema | [16,17]|
| Barbiturates and propofol | Anesthetics and sedatives | When there is elevated ICP refractory to other therapies | Depress cerebral metabolism, decreased oxygen consumption, lower ICP, and prevent seizures | [18] |
| Heparin, LMWH | Anticoagulants | Within 24–48 h of injury | Prevention of venous thromboembolism | [19] |
| Phenytoin, levetiracetam, and valproate | Antiepileptics | Within 7 days of injury | Reduce the incidence of early seizures but does not prevent the later development of epilepsy | [31] |
| Paracetamol and NSAIDs | Antipyretics | If fever | Maintenance of normothermia | [32,33] |
| **Post-acute phase** |                |                 |                       |           |
| SSRIs | Block the reabsorption of serotonin into neurons. | Weeks to months | Improve post-TBI depression, apathy, pathological laughing and crying; prevent the later onset of depression | [36–39,41–45,145] |
Table 1. Cont.

| Pharmaceutical Agents | Effects on CNS | Timing of Usage | Role in TBI Treatment | Reference |
|------------------------|----------------|-----------------|-----------------------|-----------|
| SNRIs                  | Block the reuptake of serotonin and noradrenaline | Weeks to months | Improve post-TBI depression | [46,47] |
| Trazodone              | Serotonin antagonist and reuptake inhibitor     | Weeks to months | Mixed results on sleep | [49]      |
| TCAs                   | Block the reuptake of serotonin and norepinephrine | Weeks to months | Treatment of post-TBI depression | [50]      |
| Buspirone              | Agonist of 5-HT1A receptor                       | Weeks to months | Reduce anxiety in patients with TBI | [54]      |
| Typical and atypical antipsychotics | Block the dopamine receptors | Weeks to months | Improve post-TBI psychosis | [55–63] |
| Levodopa/carbidopa     | Agonist of Dopamine receptor                    | Weeks to months | To improve consciousness | [65]      |
| Bromocriptine          | Agonist of the D2 receptor                      | Weeks to months | To improve arousal       | [66]      |
| Prazosin               | Block the α1 receptor                           | Weeks to months | Reduce daytime sleepiness, improve headaches, and improve cognition | [68]      |
| Beta blockers          | Block the β-adrenergic receptors                | Weeks to months | Reduce post-TBI agitation | [69]      |
| Amantadine             | Antagonist of the NMDA-type glutamate receptor  | Weeks to months | Improve the pace of functional recovery. Improve early arousal in the acute phase of TBI | [37,71–73] |
| Lamotrigine            | Sodium channel blocker                          | Weeks to months | Reduce aggressive behavior in TBI patients | [74]      |
| Modafinil              | Central nervous system stimulant                | Weeks to months | Could improve excessive daytime sleepiness and sleep latency | [75,77] |
| Methylphenidate        | Central nervous system stimulant                | Weeks to months | Could improve post-TBI attention and processing speed | [78–81] |
| Lisdexamfetamine dimesylate | Central nervous system stimulant            | Weeks to months | Improve attention and working memory | [82]      |
| Rivastigmine and donepezil | Inactivate the cholinesterases               | Weeks to months | Could improve memory in some subgroups of patients | [85]      |
| Benzodiazepines        | Agonist of GABA receptor                        | Weeks to months | Generally to be avoided; may impair attention, coordination, memory, and increase sedation | [86,87] |
| Pharmaceutical Agents | Effects on CNS | Timing of Usage | Role in TBI Treatment | Reference |
|------------------------|----------------|-----------------|-----------------------|-----------|
| Acute phase            |                |                 |                       |           |
| Zolpidem               | Agonist of GABA receptor | Weeks to months | Could cause a temporary response in a fraction of patients with severe TBI | [89]      |
| Melatonin              | Agonist of melatonin receptors | Weeks to months | Improve daytime sleepiness. | [92]      |
| Ramelteon              | Agonist of melatonin receptors | Weeks to months | Could improve total sleep time | [93]      |
| Balofen, tizanidine    | Block transmission at the neuromuscular junction | Weeks to months | Decrease muscle spasm, reduce muscle tone | [94–96] |
| Botulinum toxin        | Block presynaptic release of the acetylcholine at the neuromuscular junction | Weeks to months | Treatment of spasticity, improve post-TBI headache | [97,98] |

Various pharmacological treatments could affect the pathophysiology of TBI; proper treatment can reduce the detrimental effect of brain trauma in the acute and post-acute phases, and improve the overall prognosis. In this review, we have summarized medications based on clinical evidence and usage, though more clinical studies should be carried out for potential pharmacologic therapies. We expect that the accumulation of clinical evidence on newer agents would eventually lead to new therapeutic strategies that eventually improve the quality of TBI care.

Author Contributions: Conceptualization, J.T., C.-J.H., and J.-Y.S.; data review, J.T., Y.-T.W., C.-J.H., and J.-Y.S.; writing, J.T., Y.-T.W., C.-J.H., and J.-Y.S.; supervision, C.-J.H. and J.-Y.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Ministry of Science and Technology (MOST), Taiwan (Grant no: 107-2314-B-038-078-, 108-2314-B-038-049-, 110-2314-B-038-091-) and Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan (Grant no: 105TMU-WFH-02, 110-phd-02. 110TMU-WFH-13).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Dewan, M.C.; Rattani, A.; Gupta, S.; Baticulon, R.E.; Hung, Y.C.; Punchak, M.; Agrawal, A.; Adeleye, A.O.; Shriime, M.G.; Rubiano, A.M.; et al. Estimating the global incidence of traumatic brain injury. J. Neurosurg. 2018, 130, 1080–1097. [CrossRef] [PubMed]
2. Carney, N.; Totten, A.M.; O’Reilly, C.; Ullman, J.S.; Hawryluk, G.W.; Bell, M.J.; Bratton, S.L.; Chesnut, R.; Harris, O.A.; Kissoon, N.; et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery 2017, 80, 6–15. [CrossRef] [PubMed]
3. dell’Aquila, M.; Maiese, A.; de Matteis, A.; Viola, R.V.; Arcangeli, M.; la Russa, R.; Fineschi, V. Traumatic brain injury: Estimate of the age of the injury based on neuroinflammation, endothelial activation markers and adhesion molecules. Histol. Histopathol. 2021, 36, 795–806. [PubMed]
4. Rocchi, A.; Chiti, E.; Maiese, A.; Turillazzi, E.; Spinetti, I. MicroRNAs: An Update of Applications in Forensic Science. Diagnostics 2020, 11, 32. [CrossRef]
5. Pinchi, E.; Frati, A.; Cantatore, S.; D’Errico, S.; Russa, R.; Maiese, A.; Palmieri, M.; Pesce, A.; Viola, R.V.; Frati, P.; et al. Acute Spinal Cord Injury: A Systematic Review Investigating miRNA Families Involved. Int. J. Mol. Sci. 2019, 20, 1841. [CrossRef]
6. Biegon, A. Considering Biological Sex in Traumatic Brain Injury. Front. Neurol. 2021, 12, 576366. [CrossRef] [PubMed]
7. Mikolić, A.; van Klaveren, D.; Groeniger, J.O.; Wiegers, E.J.A.; Lingsma, H.F.; Zeldovich, M.; von Steinbüchel, N.; Maas, A.I.R.; van Lennep, J.E.R.; Polinder, S. Differences between Men and Women in Treatment and Outcome after Traumatic Brain Injury. *J. Neurotrauma* **2021**, *38*, 235–251. [CrossRef] [PubMed]

8. Crash, T. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): A randomised, placebo-controlled trial. *Lancet*** **2019**, *394*, 1713–1723.

9. Santing, J.A.L.; van den Brand, C.L.; Jellema, K. Traumatic Brain Injury in Patients Receiving Direct Oral Anticoagulants. *J. Emerg. Med.* **2021**, *60*, 285–291. [CrossRef]

10. Frontera, J.A.; Lewin, J.J., 3rd; Rabinstein, A.A.; Aisiku, I.P.; Alexandrov, A.W.; Cook, A.M.; del Zoppo, G.J.; Kumar, M.A.; Peerschke, E.I.; Stiefel, M.F.; et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. *Neurocritical Care* **2016**, *24*, 6–46. [CrossRef]

11. Shin, S.S.; Marsh, E.B.; Ali, H.; Nyquist, P.A.; Hanley, D.F.; Ziai, W.C. Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin K Antagonists. *Neurocritical Care* **2020**, *32*, 407–418. [CrossRef] [PubMed]

12. Yasaki, M.; Sakata, T.; Minematsu, K.; Naritomi, H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. *Thromb. Res.* **2002**, *108*, 25–30. [CrossRef]

13. Chang, B.S.; Lowenstein, D.H. Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury: Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* **2003**, *60*, 10–16. [CrossRef]

14. Alnemari, A.M.; Krafcik, B.M.; Mansour, T.R.; Gaudin, D. A Comparison of Pharmacologic Therapeutic Agents Used for the Reduction of Intracranial Pressure After Traumatic Brain Injury. *World Neurosurg.* **2017**, *106*, 509–528. [CrossRef] [PubMed]

15. Burgess, S.; Abu-Laban, R.B.; Slavik, R.S.; Vu, E.N.; Zed, P.J. A Systematic Review of Randomized Controlled Trials Comparing Hypertonic Sodium Solutions and Mannitol for Traumatic Brain Injury: Implications for Emergency Department Management. *Ann. Pharm.* **2016**, *50*, 291–300. [CrossRef]

16. Shashin, S.S.; Marsh, E.B.; Ali, H.; Nyquist, P.A.; Hanley, D.F.; Ziai, W.C. Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin K Antagonists. *Neurocritical Care* **2020**, *32*, 407–418. [CrossRef] [PubMed]

17. Margolick, J.; Dandurand, C.; Duncan, K.; Chen, W.; Evans, D.C.; Sekhon, M.S.; Garraway, N.; Griesdale, D.E.G.; Gooderham, P.; et al. Subclinical early posttraumatic seizures detected by continuous EEG monitoring in a consecutive pediatric cohort. *Epilepsia* **2012**, *53*, 20–24. [CrossRef] [PubMed]

18. Thompson, K.; Pohlmann-Eden, B.; Campbell, L.A.; Abel, H. Pharmacological treatments for preventing epilepsy following traumatic head injury. *Cochrane Database Syst. Rev.* **2015**, *8*, Cd009900. [CrossRef]

19. Temkin, N.R.; Dikmen, S.S.; Wilensky, A.J.; Keihm, J.; Chabal, S.; Winn, H.R. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. *N. Engl. J. Med.* **1990**, *323*, 497–502. [CrossRef]

20. Schierhout, G.; Roberts, I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. *Cochrane Database Syst. Rev.* **2001**, *4*, Cd001073. [CrossRef]

21. Hameed, S.M. A Systematic Review of the Risks and Benefits of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury. *J. Trauma Acute Care Surg.* **2014**, *77*, 417–421. [CrossRef] [PubMed]

22. Margolick, J.; Dandurand, C.; Duncan, K.; Chen, W.; Evans, D.C.; Sekhon, M.S.; Garraway, N.; Griesdale, D.E.G.; Gooderham, P.; et al. Subclinical early posttraumatic seizures detected by continuous EEG monitoring in a consecutive pediatric cohort. *Epilepsia* **2012**, *53*, 20–24. [CrossRef] [PubMed]

23. Thompson, K.; Pohlmann-Eden, B.; Campbell, L.A.; Abel, H. Pharmacological treatments for preventing epilepsy following traumatic head injury. *Cochrane Database Syst. Rev.* **2015**, *8*, Cd009900. [CrossRef]

24. Temkin, N.R.; Dikmen, S.S.; Wilensky, A.J.; Keihm, J.; Chabal, S.; Winn, H.R. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. *N. Engl. J. Med.* **1990**, *323*, 497–502. [CrossRef]

25. Schierhout, G.; Roberts, I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. *Cochrane Database Syst. Rev.* **2001**, *4*, Cd001073. [CrossRef]

26. Hameed, S.M. A Systematic Review of the Risks and Benefits of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury. *J. Trauma Acute Care Surg.* **2014**, *77*, 417–421. [CrossRef] [PubMed]

27. Chang, B.S.; Lowenstein, D.H. Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury: Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* **2003**, *60*, 10–16. [CrossRef]

28. Zafar, S.N.; Khan, A.A.; Ghauri, A.A.; Shamim, M.S. Phe}
31. Wat, R.; Mammi, M.; Paredes, J.; Haines, J.; Alasmari, M.; Liew, A.; Lu, V.M.; Arnaout, O.; Smith, T.R.; Gormley, W.B.; et al. The Effectiveness of Antiepileptic Medications as Prophylaxis of Early Seizure in Patients with Traumatic Brain Injury Compared with Placebo or No Treatment: A Systematic Review and Meta-Analysis. World Neurosurg. 2019, 122, 433–440. [CrossRef] [PubMed]

32. Puccio, A.M.; Fischer, M.R.; Jankowitz, B.T.; Yonas, H.; Darby, J.M.; Okonkwo, D.O. Induced normothermia attenuates intracranial hypertension and reduces fever burden after severe traumatic brain injury. Neurocritical Care 2009, 11, 82–87. [CrossRef] [PubMed]

33. Oddo, M.; Nduom, E.; Frangos, S.; MacKenzie, L.; Chen, L.; Maloney-Wilensky, E.; Kofke, W.A.; Levine, J.M.; LeRoux, P.D. Acute lung injury is an independent risk factor for brain hypoxia after severe traumatic brain injury. Neurosurgery 2010, 67, 338–344. [CrossRef] [PubMed]

34. Selassie, A.W.; Zaloshnja, E.; Langlois, J.A.; Miller, T.; Jones, P.; Steiner, C. Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J. Head Trauma Rehabil. 2008, 23, 123–131. [CrossRef] [PubMed]

35. Hoehn-Saric, R.; Lipsey, J.R.; McLeod, D.R. Apathy and indifference in patients on fluvoxamine and fluoxetine. J. Psychopharmacol. 1998, 12, 453–456. [CrossRef] [PubMed]

36. Caschka, W.P.; Meyer, A.; Schier, K.R.; Fröschler, W. Treatment of Pathological Crying with Citalopram. Pharmacopsychiatry 2001, 34, 254–258. [CrossRef] [PubMed]

37. Rahropoort, M.J.; Chan, F.; Lancot, K.; Herrmann, N.; McCullagh, S.; Feinstein, A. An open-label study of citalopram for major depression following traumatic brain injury. J. Psychopharmacol. 2008, 22, 860–864. [CrossRef] [PubMed]

38. Novack, T.A.; Baños, J.H.; Brunner, R.; Rentoe, S.; Meythaler, J.M. Impact of early administration of sertraline on depressive symptoms in the first year after traumatic brain injury. J. Neurotrauma 2009, 26, 1921–1928. [CrossRef] [PubMed]

39. Jorge, R.E.; Acion, L.; Burin, D.I.; Robinson, R.G. Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury: A Randomized Clinical Trial. JAMA Psychiatry 2016, 73, 1041–1047. [CrossRef] [PubMed]

40. Meythaler, J.M.; Depalma, L.; Devivo, M.J.; Guin-Renfroe, S.; Novack, T.A. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj. 2001, 15, 321–331. [CrossRef] [PubMed]

41. Wurtzel, H.S.; Oster, T.J.; Anderson, C.A.; Arciniegas, D.B. Pathological Laughing and Crying. CNS Drugs 2008, 22, 531–545. [CrossRef] [PubMed]

42. Kaschka, W.P.; Meyer, A.; Schier, K.R.; Fröscher, W. Treatment of Pathological Crying with Citalopram. Pharmacopsychiatry 2001, 34, 254–258. [CrossRef] [PubMed]

43. Nahas, Z.; Arlinghaus, K.A.; Kotrla, K.J.; Clearman, R.R.; George, M.S. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J. Neuropsychiatry Clin. Neurosci. 1998, 10, 453–455. [CrossRef] [PubMed]

44. Müller, U.; Murai, T.; Bauer-Wittmund, T.; von Cramon, D.Y. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj. 1999, 13, 805–811. [CrossRef] [PubMed]

45. Kanetani, K.; Kimura, M.; Endo, S. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury. J. Nippon. Med. Sch. 1999, 66, 343–345. [CrossRef] [PubMed]

46. Ripley, D.L.; Morey, C.E.; Gerber, D.; Harrison-Felix, C.; Brenner, L.A.; Pretz, C.R.; Cusick, C.; Wenes, K. Atomoxetine for attention deficits following traumatic brain injury: Results from a randomized controlled trial. Brain Inj. 2014, 28, 1514–1522. [CrossRef] [PubMed]

47. Curran, H.V.; Sakulspripon, M.; Lader, M. Antidepressants and human memory: An investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology 1988, 95, 520–527. [CrossRef]

48. Larson, E.B.; Zollman, F.S. The effect of sleep medications on cognitive recovery from traumatic brain injury. J. Head Trauma Rehabil. 2010, 25, 61–67. [CrossRef] [PubMed]

49. Wroblewski, B.A.; McColgan, K.; Smith, K.; Whyte, J.; Singer, W.D. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J. Clin. Psychopharmacol. 1990, 10, 124–128. [CrossRef] [PubMed]

50. Levy, M.; Berson, A.; Cook, T.; Bollegala, N.; Seto, E.; Tursanski, S.; Kim, J.; Sockalingam, S.; Rajput, A.; Krishnadaven, N.; et al. Treatment of agitation following traumatic brain injury: A review of the literature. NeuroRehabilitation 2005, 20, 279–306. [CrossRef] [PubMed]

51. Maryniak, O.; Manchanda, R.; Velani, A. Methotrimeprazine in the treatment of agitation in acquired brain injury patients. Brain Inj. 2001, 15, 167–174. [CrossRef] [PubMed]

52. Stanislav, S.W.; Childs, A. Evaluating the usage of droperidol in acutely agitated persons with brain injury. Brain Inj. 2000, 14, 261–265. [CrossRef] [PubMed]

53. Krieger, D.; Hansen, K.; McDermott, C.; Matthews, R.; Mitchell, R.; Bollegala, N.; Balharaq, S. Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury. NeuroRehabilitation 2003, 18, 205–208. [CrossRef] [PubMed]
58. Kim, E.; Bijlani, M. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. *J. Neuropsychiatry Clin. Neurosci.* **2006**, *18*, 547–549. [CrossRef]

59. Michals, M.L.; Crismon, M.L.; Roberts, S.; Childs, A. Clozapine response and adverse effects in nine brain-injured patients. *J. Clin. Psychopharmacol.* **1993**, *13*, 198–203. [CrossRef]

60. Noé, E.; Ferri, J.; Trener, C.; Chirivella, J. Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia. *Behav. Neurol.* **2007**, *18*, 7–11. [CrossRef]

61. Umene-Nakano, W.; Yoshimura, R.; Okamoto, T.; Hori, N.; Nakamura, J. Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: A case report. *Gen. Hosp. Psychiatry* **2013**, *35*, e7–e9. [CrossRef] [PubMed]

62. Butler, P.V. Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury. *Aust. N. Z. J. Psychiatry* **2000**, *34*, 684–687. [CrossRef] [PubMed]

63. Bde, M.V.; Frais, H.A.; Nicolato, R.; Caramelli, P. Posttraumatic brain injury psychosis successfully treated with olanzapine. *Prog. Neuro-Psycho Pharmacol. Biol. Psychiatry* **2010**, *34*, 233–235.

64. Arciniegas, D.B.; Harris, S.N.; Brousseau, K.M. Psychosis following traumatic brain injury. *Int. Rev. Psychiatry* **2003**, *15*, 328–340. [CrossRef] [PubMed]

65. Krimchansky, B.Z.; Keren, O.; Sazbon, L.; Grosz, Z. Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment. *Brain Inj.* **2004**, *18*, 1099–1105. [CrossRef] [PubMed]

66. Passler, M.A.; Riggs, R.V. Positive outcomes in traumatic brain injury-vegetative state: Patients treated with bromocriptine. *Arch. Phys. Med. Rehabil.* **2001**, *82*, 311–315. [CrossRef] [PubMed]

67. Whyte, J.; Vaccaro, M.; Grieb-Neff, P.; Hart, T.; Polansky, M.; Coslett, H.B. The effects of bromocriptine on attention deficits after traumatic brain injury: A placebo-controlled pilot study. *J. Am. Phys. Med. Rehabil.* **2008**, *87*, 85–99. [CrossRef]

68. Ruff, R.L.; Riechers, R.G., II.; Wang, X.F.; Piero, T.; Ruff, S.S. For veterans with mild traumatic brain injury, improved posttraumatic stress disorder severity and sleep correlated with symptomatic improvement. *J. Rehabil. Res. Dev.* **2012**, *49*, 1305–1320. [CrossRef]

69. Fleminger, S.; Greenwood, R.J.; Oliver, D.L. Pharmacological management for agitation and cognition after traumatic brain injury. *Cochrane Database Syst. Rev.* **2006**, Cd003299. [CrossRef]

70. Rappaport, M.; Hall, K.M.; Hopkins, K.; Belleza, T.; Cope, D.N. Disability rating scale for severe head trauma: Coma to community. *Arch. Phys. Med. Rehabil.* **1982**, *63*, 118–123.

71. Zafonte, R.D.; Watanabe, T.; Mann, N.R. Amantadine: A potential treatment for the minimally conscious state. *Brain Inj.* **1998**, *12*, 617–621. [CrossRef] [PubMed]

72. Meythaler, J.M.; Brunner, R.C.; Johnson, A.; Novack, T.A. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized trial. *J. Head Trauma Rehabil.* **2002**, *17*, 300–313. [CrossRef] [PubMed]

73. Sawyer, E.; Mauro, L.S.; Ohlinger, M.J. Amantadine enhancement of arousal and cognition after traumatic brain injury. *Ann. Pharmac.* **2008**, *42*, 247–252. [CrossRef] [PubMed]

74. Pachet, A.; Friesen, S.; Winkelaar, D.; Gray, S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. *Brain Inj.* **2003**, *17*, 715–722. [CrossRef]

75. Kaiser, P.R.; Valko, P.O.; Werth, E.; Thomann, J.; Meier, J.; Stocker, R.; Bassetti, C.L.; Baumann, C.R. Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. *Neurology* **2010**, *75*, 1780–1785. [CrossRef]

76. Jha, A.; Weintraub, A.; Allshouse, A.; Cusick, C.; Kittelson, J.; Harrison-Felix, C.; Whitenec, G.; Gerber, D. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. *J. Head Trauma Rehabil.* **2008**, *23*, 52–63. [CrossRef]

77. Menz, S.J.; Yang, R.; Lankford, A. Armofadinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: A 12-week, randomized, double-blind study followed by a 12-month open-label extension. *J. Clin. Sleep Med.* **2014**, *10*, 1181–1191. [CrossRef]

78. Whyte, J.; Hart, T.; Vaccaro, M.; Grieb-Neff, P.; Risser, A.; Polansky, M.; Coslett, H.B. Effects of methylphenidate on attention deficits after traumatic brain injury: A multidimensional, randomized, controlled trial. *Am. J. Phys. Med. Rehabil.* **2004**, *83*, 401–420. [CrossRef]

79. Willmott, C.; Ponsford, J. Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: A randomised, crossover, double blind, placebo controlled inpatient trial. *J. Neurol. Neurosurg. Psychiatry* **2009**, *80*, 552–557. [CrossRef]

80. Sivan, M.; Neumann, V.; Kent, R.; Stroud, A.; Bhakta, B.B. Pharmacotherapy for treatment of attention deficits after non-progressive acquired brain injury. A systematic review. *Clin. Rehabil.* **2010**, *24*, 110–121. [CrossRef]

81. McAllister, T.W.; Zafonte, R.; Jain, S.; Flashman, L.A.; George, M.S.; Grant, G.A.; He, F.; Lohr, J.B.; Andaluz, N.; Summerall, L.; et al. Stein, Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. *Neuropsychopharmacol. 2016*, **41**, 1191–1198. [CrossRef] [PubMed]

82. Tramontana, M.G.; Cowan, R.L.; Zald, D.; Prokop, J.W.; Guillamondegui, O. Traumatic brain injury-related attention deficits: Treatment outcomes with lisdexamfetamine dimesylate (Vyvanse). *Brain Inj.* **2014**, *28*, 1461–1472. [CrossRef] [PubMed]

83. Ponsford, J.; Spitz, G.; Hicks, A.J. Highlights in traumatic brain injury research in 2021. *Lancet Neurol.* **2022**, *21*, 5–6. [CrossRef]
84. Tenovuo, O.; Alin, J.; Helenius, H. A randomized controlled trial of rivastigmine for chronic sequelae of traumatic brain injury—what it showed and taught? Brain Inj. 2009, 23, 548–558. [CrossRef] [PubMed]
85. Silver, J.M.; Koumaras, B.; Meng, X.; Potkin, S.G.; Reyes, P.E.; Harvey, P.D.; Katz, D.J.; Gunay, I.; Arciniega, D.B. Long-term effects of rivastigmine capsules in patients with traumatic brain injury. Brain Inj. 2009, 23, 123–132. [CrossRef]
86. Barker, M.J.; Greenwood, K.M.; Jackson, M.; Crowe, S.F. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: A meta-analysis. Arch. Clin. Neuropsychol. 2004, 19, 437–454. [CrossRef]
87. Barker, M.J.; Greenwood, K.M.; Jackson, M.; Crowe, S.F. Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs 2004, 18, 37–48. [CrossRef]
88. Ouellet, M.C.; Beaulieu-Bonneau, S.; Morin, C.M. Sleep-wake disturbances after traumatic brain injury. Lancet Neurol. 2015, 14, 746–757. [CrossRef]
89. Whyte, J.; Rajan, R.; Rosenbaum, A.; Katz, D.; Kalmar, K.; Seel, R.; Greenwald, B.; Zafonte, R.; Demarest, D.; Brunner, R.; et al. Zolpidem and restoration of consciousness. Am. J. Phys. Med. Rehabil. 2014, 93, 101–113. [CrossRef]
90. Williams, S.T.; Conte, M.M.; Goldfine, A.M.; Noirhomme, Q.; Gosseries, O.; Thonnard, M.; Beattie, B.; Hersh, J.; Katz, D.L.; Victor, J.D.; et al. Common resting brain dynamics indicate a possible mechanism underlying zolpidem response in severe brain injury. Elife 2013, 2, e01157. [CrossRef]
91. Du, B.; Shan, A.; Zhang, Y.; Zhong, X.; Chen, D.; Cai, K. Zolpidem arouses patients in vegetative state after brain injury: Quantitative evaluation and indications. Am. J. Med. Sci. 2014, 347, 178–182. [CrossRef]
92. Kempt, S.; Biswas, R.; Neumann, V.; Coughlan, A. The value of melatonin for sleep disorders occurring post-head injury: A pilot RCT. Brain Inj. 2004, 18, 911–919. [CrossRef] [PubMed]
93. Lequerica, A.; Jasey, N.; Tremont, J.N.P.; Chiaravalloti, N.D. Pilot Study on the Effect of Ramelteon on Sleep Disturbance After Traumatic Brain Injury: Preliminary Evidence From a Clinical Trial. Arch. Phys. Med. Rehabil. 2015, 96, 1802–1809. [CrossRef] [PubMed]
94. Meythaler, J.M.; Clayton, W.; Davis, L.K.; Guin-Renfroe, S.; Brunner, R.C. Orally delivered baclofen to control spastic hypertonia in acquired brain injury. J. Head Trauma Rehabil. 2013, 19, 101–108. [CrossRef]
95. Posteraro, F.; Calandriello, B.; Galli, R.; Logi, F.; Iardella, L.; Bordi, L. Timing of intrathecal baclofen therapy in persons with acquired brain injury: Influence on outcome. Brain Inj. 2013, 27, 1671–1675. [CrossRef] [PubMed]
96. Meythaler, J.M.; Guin-Renfroe, S.; Johnson, A.; Brunner, R.M. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch. Phys. Med. Rehabil. 2012, 93, 1155–1163. [CrossRef]
97. Yablon, S.A.; Agana, B.T.; Ivanhoe, C.B.; Boake, C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: An open-labeled trial. Neurology 1996, 47, 939–944. [CrossRef]
98. Yerry, J.A.; Kuehn, D.; Finkel, A.G. Onabotulinum toxin a for the treatment of headache in service members with a history of mild traumatic brain injury. Headache 2017, 55, 395–406. [CrossRef]
99. Lump, D.; Moyer, M. Paroxysmal sympathetic hyperactivity after severe brain injury. Curr. Neurol. Neurosci. Rep. 2014, 14, 494. [PubMed]
100. Blackman, J.A.; Patrick, P.D.; Buck, M.L.; Rust, R.S., Jr. Paroxysmal autonomic instability with dystonia after brain injury. Arch. Neurol. 2004, 61, 321–328. [CrossRef]
101. Baguley, I.J.; Heriseanu, R.E.; Gurka, J.A.; Nordenbo, A.; Cameron, I.D. Gabapentin in the management of dysautonomia with head injury—outcomes at 6 months. Lancet 2005, 365, 1957–1959. [PubMed]
102. Roberts, I.; Yates, D.; Sandercop, P.; Farrell, B.; Wasserberg, J.; Lomas, G.; Cottingham, R.; Svoboda, P.; Brayley, N.; Mazzairac, G.; et al. Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial. Lancet 2004, 364, 1321–1328. [PubMed]
103. Edwards, P.; Arango, M.; Balica, L.; Cottingham, R.; El-Sayed, H.; Farrell, B.; Fernandes, J.; Gogichaisvili, T.; Golden, N.; Hertzenberg, B.; et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005, 365, 784–793. [PubMed]
104. Wright, D.W.; Yeatts, S.D.; Silbergleit, R.; Palesch, Y.Y.; Hertzberg, V.S.; Frankel, M.; Goldstein, F.C.; Caveney, A.F.; Howlett-Smith, H.; Bengelink, E.M.; et al. Very early administration of progesterone for acute traumatic brain injury. N. Engl. J. Med. 2014, 371, 2457–2466. [CrossRef]
105. Skolnick, B.E.; Maas, A.I.; Narayan, R.K.; van der Hoop, R.G.; MacAllister, T.; Ward, J.D.; Nelson, N.R.; Stocchetti, N. A clinical trial of progesterone for severe traumatic brain injury. N. Engl. J. Med. 2014, 371, 2457–2467. [CrossRef]
106. Xiao, G.; Wei, J.; Yan, W.; Wang, W.; Lu, Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: A randomized controlled trial. Crit. Care 2008, 12, R61. [CrossRef]
110. Sinha, S.; Raheja, A.; Samson, N.; Goyal, K.; Bhoi, S.; Selvi, A.; Sharma, P.; Sharma, B.S. A randomized placebo-controlled trial of progesterone with or without hypothermia in patients with acute severe traumatic brain injury. *Neuro. India* 2017, 65, 1304–1311. [CrossRef]

111. Nichol, A.; French, C.; Little, L.; Haddad, S.; Presneill, J.; Arabi, Y.; Bailey, M.; Cooper, D.J.; Duranteau, J.; Huet, O.; et al. Erythropoietin in traumatic brain injury (EPO-TBI): A double-blind randomised controlled trial. *Lancet* 2015, 386, 2499–2506. [CrossRef]

112. Lee, J.; Cho, Y.; Choi, K.S.; Kim, W.; Jang, B.H.; Shin, H.; Ahn, C.; Lim, T.H.; Yi, H.J. Efficacy and safety of erythropoietin in patients with traumatic brain injury: A systematic review and meta-analysis. *Am. J. Emerg. Med.* 2019, 37, 1101–1107. [CrossRef] [PubMed]

113. Liu, M.; Wang, A.J.; Chen, Y.; Zhao, G.; Jiang, Z.; Wang, X.; Shi, D.; Zhang, T.; Sun, B.; He, H.; et al. Efficacy and safety of erythropoietin for traumatic brain injury. *BMC Neurol.* 2020, 20, 399. [CrossRef] [PubMed]

114. Bai, X.F.; Gao, Y.K. Recombinant human erythropoietin for treating severe traumatic brain injury. *Medicine* 2018, 97, e5932. [CrossRef] [PubMed]

115. Temkin, N.R.; Anderson, G.D.; Winn, H.R.; Ellenbogen, R.G.; Britz, G.W.; Schuster, J.; Lucas, T.; Newell, D.W.; Mansfield, P.N.; Machamer, J.E.; et al. Magnesium sulfate for neuroprotection after traumatic brain injury: A randomised controlled trial. *Lancet Neurol.* 2007, 6, 29–38. [CrossRef]

116. Lyons, M.W.H.; Blackshaw, W.J. Does magnesium sulfate have a role in the management of severe traumatic brain injury in civilian and military populations? A systematic review and meta-analysis. *J. R. Army Med. Corp.* 2018, 164, 442–449. [CrossRef]

117. Hatton, J.; Rosbolt, B.; Empey, P.; Kryscio, R.; Young, B. Dosing and safety of cyclosporine in patients with severe brain injury. *J. Neurosurg.* 2008, 109, 699–707. [CrossRef]

118. Aminmansour, B.; Fard, S.A.; Habibabadi, M.R.; Moein, P.; Norouzi, R.; Naderan, M. The efficacy of Cyclosporine-A on Diffuse Axonal Injury after Traumatic Brain Injury. *Adv. Biomed. Res.* 2014, 3, 35.

119. Jha, R.M.; Bell, J.; Citerio, G.; Hemphill, J.C.; Kimberly, W.T.; Narayan, R.K.; Sahuquillo, J.; Sheth, K.N.; Simard, J.M. Role of Sulfonyleurea Receptor 1 and Glibenclamide in Traumatic Brain Injury: A Review of the Evidence. *Int. J. Mol. Sci.* 2020, 21, 409. [CrossRef]

120. Zafaroodost, P.; Ghasemi, A.A.; Salehpour, F.; Piroci, C.; Ziaeei, E. Evaluation of the Effect of Glibenclamide in Patients With Diffuse Axonal Injury Due to Moderate to Severe Head Trauma. *Trauma Mon.* 2016, 21, e25113. [CrossRef]

121. Khalili, H.; Derakhshan, N.; Niakan, A.; Ghaffarpasand, F.; Salehi, M.; Eshraghian, H.; Shakibafard, A.; Zahabi, B.H.; Shin, H.; Ahn, C.; Lim, T.H.; Yi, H.J. Effects of erythropoietin in traumatic brain injury patients with traumatic brain injury: A systematic review and meta-analysis. *Am. J. Emerg. Med.* 2019, 37, 1101–1107. [CrossRef] [PubMed]

122. Mansi, I.A.; English, J.L.; Alvarez, C.A.; Mortensen, E.M.; Pugh, M.J. Statins in survivors of traumatic brain injury: A propensity score-matched analysis. *Brain Inj.* 2020, 34, 1367–1374. [CrossRef]

123. Sultan, W.; Sapkota, A.; Khurshid, H.; Qureshi, I.A.; Jahan, N.; Went, T.R.; Dominic, J.L.; Win, M.; Kannan, A.; Tara, A.; et al. Statins’ Effect on Cognitive Outcome After Traumatic Brain Injury: A Systematic Review. *Cureus* 2021, 13, e16953. [CrossRef] [PubMed]

124. Eisenberg, H.M.; Shenton, M.E.; Pasternak, O.; Simard, J.M.; Okonkwo, D.O.; Aldrich, C.; He, F.; Jain, S.; Hayman, E.G. Magnetic Resonance Imaging Pilot Study of Intravenous Glyburide in Traumatic Brain Injury. *J. Neurotrauma* 2020, 37, 185–193. [CrossRef] [PubMed]

125. Cekic, M.; Cutler, S.M.; VanLandingham, J.W.; Stein, D.G. Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. *Neurobiol. Aging* 2011, 32, 864–874. [CrossRef]

126. Conte, V.; Uryu, K.; Fujimoto, S.; Yao, Y.; Rokach, J.; Longhi, L.; Trojanowski, J.Q.; Lee, V.M.; McIntosh, T.K.; Pratico, D. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. *J. Neurochem.* 2004, 90, 758–764. [CrossRef]

127. Wen, L.; You, W.; Wang, H.; Meng, Y.; Feng, J.; Yang, X. Polarization of Microglia to the M2 Phenotype in a Peroxisome Proliferator-Activated Receptor Gamma-Dependent Manner Attenuates Axonal Injury Induced by Traumatic Brain Injury in Mice. *J. Neurotrauma* 2018, 35, 2330–2340. [CrossRef]

128. Yi, J.H.; Park, S.W.; Brooks, N.; Lang, B.T.; Vemuganti, R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. *Brain Res.* 2008, 1244, 164–172. [CrossRef]

129. Peterson, T.C.; Hoane, M.R.; McConomy, K.S.; Farin, F.M.; Bammler, T.K.; MacDonald, J.W.; Kantor, E.D.; Anderson, G.D. A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury. *J. Neurotrauma* 2015, 32, 765–779. [CrossRef] [PubMed]

130. Goftus, A.M.; Anderson, G.D.; Hoane, M. Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury. *Oxidative Med. Cell. Longev.* 2010, 3, 145–152. [CrossRef]
133. Haar, C.V.; Emery, M.A.; Hoane, M.R. Chronic folic acid administration confers no treatment effects in either a high or low dose following unilateral controlled cortical impact injury in the rat. *Restor. Neurol. Neurosci.* **2012**, *30*, 291–302.

134. Naim, M.Y.; Friess, S.; Smith, C.; Ralston, J.; Ryall, K.; Helfaer, M.A.; Margulies, S.S. Folic acid enhances early functional recovery in a piglet model of pediatric head injury. *Dev. Neurosci.* **2010**, *32*, 466–479. [CrossRef] [PubMed]

135. Scrimgeour, A.G.; Condlin, M.L. Nutritional treatment for traumatic brain injury. *J. Neurotrauma* **2014**, *31*, 989–999. [CrossRef]

136. McClain, C.J.; Twyman, D.L.; Ott, L.G.; Rapp, R.P.; Tibbs, P.A.; Norton, J.A.; Kasarskis, E.J.; Dempsey, R.J.; Young, B. Serum and urine zinc response in head-injured patients. *J. Neurosurg.* **1986**, *64*, 224–230. [CrossRef]

137. Cope, E.C.; Morris, D.R.; Scrimgeour, A.G.; Levenson, C.W. Use of zinc as a treatment for traumatic brain injury in the rat: Effects on cognitive and behavioral outcomes. *Neurorehabilit. Neural Repair* **2012**, *26*, 907–913. [CrossRef]

138. Cope, E.C.; Morris, D.R.; Gower-Winter, S.D.; Brownstein, N.C.; Levenson, C.W. Effect of zinc supplementation on neuronal precursor proliferation in the rat hippocampus after traumatic brain injury. *Exp. Neurol.* **2016**, *279*, 96–103. [CrossRef]

139. Ménard, C.; Patenaude, C.; Gagné, A.M.; Massicotte, G. AMPA receptor-mediated cell death is reduced by docosahexaenoic acid but not by eicosapentaenoic acid in area CA1 of hippocampal slice cultures. *J. Neurosci. Res.* **2009**, *87*, 876–886. [CrossRef]

140. Begum, G.; Yan, H.Q.; Li, L.; Singh, A.; Dixon, C.E.; Sun, D. Docosahexaenoic acid reduces ER stress and abnormal protein accumulation and improves neuronal function following traumatic brain injury. *J. Neurosci.* **2014**, *34*, 3743–3755. [CrossRef]

141. Wu, A.; Ying, Z.; Schubert, D.; Gomez-Pinilla, F. Brain and spinal cord interaction: A dietary curcumin derivative counteracts locomotor and cognitive deficits after brain trauma. *Neurorehabil. Neural. Repair* **2011**, *25*, 332–342. [CrossRef] [PubMed]

142. Lin, C.J.; Chen, T.H.; Yang, L.Y.; Shih, C.M. Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death. *Cell Death Dis.* **2014**, *5*, e1147. [CrossRef] [PubMed]

143. Theadom, A.; Mahon, S.; Barker-Collo, S.; McPherson, K.; Rush, E.; Vandal, A.C.; Feigin, V.L. Enzogenol for cognitive functioning in traumatic brain injury: A pilot placebo-controlled RCT. *Eur. J. Neurol.* **2013**, *20*, 1135–1144. [CrossRef] [PubMed]

144. Baltazar, G.A.; Pate, A.J.; Panigrahi, B.; LaBoy, S.; Prosniak, R.; Mody, A.; Chandrasekhar, A. Malnutrition as measured by albumin and prealbumin on admission is associated with poor outcomes after severe traumatic brain injury. *Am. Surg.* **2015**, *81*, E61-3. [CrossRef] [PubMed]

145. Horsfield, S.A.; Rosse, R.B.; Tomasino, V.; Schwartz, B.L.; Mastropaolo, J.; Deutsch, S.I. Fluoxetine’s effects on cognitive performance in patients with traumatic brain injury. *Int. J. Psychiatry Med.* **2002**, *32*, 337–344. [CrossRef]